Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease

Sanofi's Dupixent gets FDA nod for chronic hives indication

Sanofi's Dupixent gets FDA nod for chronic hives indication Jonah.Comstock Mon, 21/04/2025 - 13:45 Bookmark this

FDA approves blockbuster Dupixent for chronic hives

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we talk lots about tariffs — how they might impact drugmakers, patients, and even Ireland. Also, Novo Nordisk challenges Medicare over drug differentiation, and more. Read the rest…

Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease

The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication. The post Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease appeared first on MedCity News.

From 2031, his star drug, a major contributor to the profits of the French laboratory, fell into the public domain. External growth was called upon to play a major role in circumventing the future sales shock.

His whole body was itchy, he thought it was an allergy and was diagnosed

Why do hives appear on the skin? These are the surprising facts you might not know. Hives, or known as urticaria, are itchy, raised welts that are found on the skin. They’re usually pink, red, or flesh colored on lighter skin and may be flesh colored or slightly lighter or darker than your skin tone on brown or black skin. At times they sting or hurt. In the majority of cases, hives are caused by an allergic reaction to a medication or food or a…

Sanofi and Regeneron's dupilumab approved by FDA for urticaria

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU)